Skip to main content
13 April 2021
Last updated:
Tuesday 13 April 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Tecentriq effective in early lung cancer

Monday 29 March 2021
Country

Switzerland

The immune checkpoint inhibitor Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in a Phase 3 study in people with early non-small cell lung cancer, Roche announced on 22 March.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Clinical Research
Company News

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

René Hoet becomes CSO at Montis Biosciences
Wednesday March 31 2021
Pan Cancer T makes board appointments
Wednesday March 31 2021
Björn Englund appointed CEO at Opterion
Wednesday March 31 2021
Sven Zimmermann joins Inotrem
Wednesday March 31 2021
New director at Mission Therapeutics
Wednesday March 31 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.